Many of you will probably know that a single national list of drugs accepted into the Cancer Drugs Fund (CDF) for England has replaced the regionally based lists that were operative before the 1st April. After a review of all drugs on the regional lists, dasatinib was one of the drugs transferred into the new national list and has now been joined by both bosutinib and ponatinib accepted into the list since April 1st. However the availability of these drugs for CML depends on a definition of a patient profile, called indications, that applicants must meet. see PDF below.
